Sie suchten nach: interlevkina (Slowenisch - Englisch)

farmakoterapevtska skupina: zaviralci interlevkina.
pharmacotherapeutic group:

iksekizumab sodi v skupino zdravil, imenovanih zaviralci interlevkina (il).
ixekizumab belongs to a group of medicines called interleukin (il) inhibitors.

normalno vaše telo izdeluje beljakovino, ki blokira škodljive učinke interlevkina-1.
normally, your body produces a protein that blocks the harmful effects of interleukin-1.

zdravilo cinqaero zavira aktivnost interlevkina-5 in zmanjša število eozinofilcev v krvi in pljučih.
cinqaero blocks interleukin-5 activity and reduces the number of eosinophils in your blood and lungs.

abatacept zmanjša t limfocitno produkcijo antigensko specifičnega tnfα, interferona-γ in interlevkina-2.
abatacept decreases antigen specific tnfα, interferon-γ, and interleukin-2 production by t lymphocytes.

farmakoterapevtska skupina: zdravila za zaviranje imunske odzivnosti, zaviralci interlevkina, oznaka atc: l04ac11.
pharmacotherapeutic group: immunosuppresants, interleukin inhibitors, atc code: l04ac11.

s tem se poveča učinkovitost interlevkina-2, zdravila, ki spodbuja imunski sistem k uničevanju rakavih celic.
this improves the effectiveness of interleukin-2, a medicine that stimulates the immune system to attack cancerous cells.

s tem se poveča učinkovitost interlevkina- 2, 7 westferry circus, canary wharf, london e14 4hb, uk tel.
when ceplene 7 westferry circus, canary wharf, london e14 4hb, uk tel.

družba bo izvedla nadaljnje študije, ki bodo podrobneje raziskale učinkovitost kombinacije zdravila ceplene in interlevkina-2 ter mehanizem delovanja te kombinacije.
the company will carry out further studies to look in more detail at the effectiveness of the combination of ceplene and interleukin-2 and at how the combination works.

priporočeni odmerek zdravila ceplene je 0, 5 mg, ki se vbrizga podkožno dvakrat dnevno, eno do tri minute po vbrizganju interlevkina- 2.
the recommended dose of ceplene is a 0.5-mg injection under the skin, twice a day, one to three minutes after an interleukin-2 injection.

priporočeni odmerek zdravila ceplene je 0,5 mg, ki se vbrizga v podkožje dvakrat dnevno, eno do tri minute po vbrizganju interlevkina-2.
the recommended dose of ceplene is a 0.5-mg injection under the skin, twice a day, one to three minutes after an interleukin-2 injection.

ustekinumab se ne more vezati na interlevkina il-12 in il-23, ki sta že vezana na receptorje il-12r1 na celični površini.
ustekinumab cannot bind to il-12 or il-23 that is already bound to il-12r1 cell surface receptors.

ustekinumab se ne more vezati na interlevkina il- 12 in il- 23, ki sta se pred tem vezala na receptorje il- 12rβ1 na celični površini.
ustekinumab cannot bind to il-12 or il-23 that is pre-bound to il-12rβ 1 cell surface receptors.

poleg tega so bolniki s hudo sepso, zdravljeni z zdravilom xigris, kazali hitrejši padec ravni interlevkina-6, splošnega pokazatelja vnetja, kar je v skladu z zmanjšanjem vnetnega odziva.
additionally, patients with severe sepsis treated with xigris had a more rapid decline in interleukin-6 levels, a global marker of inflammation, consistent with a reduction in the inflammatory response.

baziliksimab se specifično veže z veliko afiniteto (vrednost kd 0,1 nmol) na antigen cd25 na aktiviranih limfocitih t, z izraženim receptorjem za interlevkin-2 (il-2r) velike afinitete, in tako prepreči vezavo interlevkina 2, ki je odločilen signal za proliferacijo celic t pri celičnem imunskem odzivu, ki je vpleten v zavrnitev presadka.
basiliximab specifically binds with high affinity (kd-value 0.1 nm) to the cd25 antigen on activated t-lymphocytes expressing the high affinity interleukin-2 receptor (il-2r) and thereby prevents binding of interleukin-2, a critical signal for t-cell proliferation in the cellular immune response involved in allograft rejection.